DNARx is pioneering advancements in gene therapy through its proprietary platform known as HEDGES (High-level Extended Duration Gene Expression System). This innovative, nonviral gene therapy system is designed to facilitate durable expression of therapeutic genes, allowing for repeat dosing and the expression of large DNA constructs that can target multiple genes simultaneously. HEDGES addresses significant limitations associated with traditional viral delivery methods, such as restricted gene delivery capacity and immunogenicity, by providing a safer alternative that avoids DNA integration into the host genome. This platform has demonstrated the ability to maintain therapeutic levels of proteins for extended periods, ranging from weeks to over a year, depending on the specific formulation used.

The HEDGES platform is particularly versatile, enabling the expression of various therapeutic proteins, including monoclonal antibodies, and is being developed for a range of serious medical conditions, including cancer, hemophilia, and infectious diseases like influenza. DNARx's approach not only enhances the safety profile of gene therapy by minimizing potential toxicities but also allows for precise control over the duration of gene expression. This capability positions DNARx to address unmet medical needs effectively, with ongoing research and development aimed at creating novel therapeutics that leverage the unique advantages of the HEDGES system.

United States

DNARx is a company developing multiple therapeutics for major unmet medical needs, with demonstrated vaccine capabilities as well as protein expression. The company has been awarded a DARPA contract for up to $10.7 million to develop medical countermeasures against biological threats.

DNARx

Company Details